You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

21 Results
Drug
Other Name(s): Gemzar®
Dec 2023
Regimen
Cancer Type:
Gastrointestinal, 
Pancreas
Intent: Adjuvant
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Cancer Type:
Gastrointestinal, 
Pancreas
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Cancer Type:
Endocrine, 
Adrenal
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Cancer Type:
Gastrointestinal, 
Pancreas
Intent: Palliative
Jan 2023
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Apr 2023
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Locally Recurrent Unresectable or Metastatic Triple Negative Breast Cancer
Sep 2023
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Cancer Type:
Gastrointestinal, 
Pancreas
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Cancer Type:
Gastrointestinal, 
Pancreas
Intent: Palliative
Apr 2023

Pages